Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06438471 · ClinicalTrials.gov registry record · Phase 1
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
A Phase 1 study of Spinal Cord Injuries and Degenerative Disc Disease, sponsored by EicOsis Human Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06438471: Recruiting Phase 1 study of Spinal Cord Injuries and Degenerative Disc Disease, sponsored by EicOsis Human Health.
NCT06438471 is a Phase 1 study of Spinal Cord Injuries and Degenerative Disc Disease that is actively recruiting participants, run by EicOsis Human Health. The registered enrollment target is 36 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06438471, a Phase 1 study of Spinal Cord Injuries and Degenerative Disc Disease, is actively recruiting participants, sponsored by EicOsis Human Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain. Researchers will compare EC5026 to placebo. Participants will be asked to: * Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days. * Undergo physical exams, vital signs assessments, ECGs, and blood draws * Complete assessments of pain, sleep, functional status, and perception of change
Primary Outcome
All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progre
Conditions Studied
Interventions
- DRUG EC5026 oral tablet
- DRUG Placebo oral tablet
Study Locations (1)
Georgia
- AU Medical Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-02-28 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06438471 shows while recruiting
NCT06438471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (41% lower).
The record links to 5 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which EC5026 oral tablet is the first listed.
NCT06438471 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06438471 about?
NCT06438471 is a clinical study titled "Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury". The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolera...
What is the current status of trial NCT06438471?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-02-28. Estimated completion is 2027-06.
What conditions does trial NCT06438471 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Degenerative Disc Disease, Neuropathic Pain, Spinal Stenosis, Spondylosis.
What interventions are being tested in trial NCT06438471?
The interventions under investigation include: EC5026 oral tablet (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT06438471?
This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06438471 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06438471's enrollment target sits among peer trials
36 80th of 202 higher than 117 of 202 other Spinal Cord Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
RECRUITING · Phase 1
-
NVG-291 in Spinal Cord Injury Subjects
RECRUITING · Phase 1
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 1
-
Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy